Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diabetes and metabolic dysfunction-associated fatty liver disease
Timothy M. E. Davis
Metabolism (2021) Vol. 123, pp. 154868-154868
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 92
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need
Michail Kokkorakis, Chrysoula Boutari, Niki Katsiki, et al.
Metabolism (2023) Vol. 147, pp. 155664-155664
Open Access | Times Cited: 42
The Lipidomic Profile Discriminates Between MASLD and MetALD
Kai Markus Schneider, Feng Cao, Helen Huang, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 2
The cGAS-STING pathway: a therapeutic target in diabetes and its complications
Wenjie He, Xingrui Mu, Xingqian Wu, et al.
Burns & Trauma (2024) Vol. 12
Open Access | Times Cited: 13
Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
Yulino Castillo-Núñez, Paloma Almeda‐Valdés, Guillermo González-Gálvez, et al.
Current Diabetes Reports (2024) Vol. 24, Iss. 7, pp. 158-166
Closed Access | Times Cited: 9
Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study
Yajun He, Nanfang Yao, Feng Tian, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 3, pp. 102973-102973
Closed Access | Times Cited: 6
Detecting key genes relative expression orderings as biomarkers for machine learning-based intelligent screening and analysis of type 2 diabetes mellitus
Xue-Qin Xie, Changchun Wu, Cai-Yi Ma, et al.
Expert Systems with Applications (2024) Vol. 255, pp. 124702-124702
Closed Access | Times Cited: 5
The role of Andrographolide in the prevention and treatment of liver diseases
Xiao‐Yan Qin, Xi Wang, Maoying Tian, et al.
Phytomedicine (2023) Vol. 109, pp. 154537-154537
Closed Access | Times Cited: 15
Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice
Ying Wu, Jiaqiang Zhou
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 148-148
Open Access
A High Signal-to-Noise Ratio NIR Fluorescent Probe for Viscosity Detection in NAFLD Diagnosis
Junlei Hao, Suntao Shi, Yaoling Zhang, et al.
Sensors and Actuators B Chemical (2025), pp. 137581-137581
Closed Access
Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021 to 2045
Chengxia Kan, Kexin Zhang, Yuqun Wang, et al.
Annals of Hepatology (2025), pp. 101898-101898
Open Access
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Qingfu Dong, Haolin Bao, Jiangang Wang, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 11
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin‐Nan Cheng, Wen‐Jone Chen, Charles Jia‐Yin Hou, et al.
Clinical and Molecular Hepatology (2023) Vol. 30, Iss. 1, pp. 16-36
Open Access | Times Cited: 10
Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort
Yao-Wei Zou, Qianhua Li, Jing‐Wei Gao, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 14
A Study of Biomarkers Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes
Ion Cristian Efrem, Maria Moţa, Ionela Mihaela Vladu, et al.
Diagnostics (2022) Vol. 12, Iss. 10, pp. 2426-2426
Open Access | Times Cited: 14
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Jia Yu, Dongze Li, Yi You, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 8
The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease
Yingying Hu, Fan Zhou, Fang Lei, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 7
Branched‐Chain Amino Acids in Computed Tomography–Defined Adipose Depots and Coronary Artery Disease: A PROMISE Trial Biomarker Substudy
Elizabeth Zhao, Stephanie N. Giamberardino, Neha J. Pagidipati, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 11
Open Access | Times Cited: 7
Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer?
Binxin Cui, Lin Lin, Bangmao Wang, et al.
Pharmacological Research (2021) Vol. 175, pp. 106022-106022
Closed Access | Times Cited: 16
Combined exposure to PM2.5 and high-fat diet facilitates the hepatic lipid metabolism disorders via ROS/miR-155/PPARγ pathway
Zhou Du, Lisen Lin, Yang Li, et al.
Free Radical Biology and Medicine (2022) Vol. 190, pp. 16-27
Closed Access | Times Cited: 11
Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study
Zhihao Wei, Zhe Huang, Zongshuang Song, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 6
The Coumarin-Derivative Esculetin Protects against Lipotoxicity in Primary Rat Hepatocytes via Attenuating JNK-Mediated Oxidative Stress and Attenuates Free Fatty Acid-Induced Lipid Accumulation
Mengmeng Xia, Zongmei Wu, Junyu Wang, et al.
Antioxidants (2023) Vol. 12, Iss. 11, pp. 1922-1922
Open Access | Times Cited: 6
Integrating network analysis and experimental validation to reveal the mechanism of pinocembrin in alleviating high glucose and free fatty acid-induced lipid accumulation in HepG2 cells
Kun Hu, Yongjin Sun, Jie Wang, et al.
Journal of Functional Foods (2023) Vol. 110, pp. 105879-105879
Open Access | Times Cited: 5
Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women
Yayun Lu, Lingxia Ge, Hao Yang, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 607-617
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top